Guidance on the Harmonization of Compendial Standards Published
FDA released draft guidance on using the USP pending monograph process in the drug application process.
FDA released draft guidance on July 10, 2019 that assists applicants in initiating revisions to an existing monograph or the development of a new monograph under the United States Pharmacopeial Convention–Pending Monography Process (USP–PMP) during FDA’s evaluation of a drug substance master file or drug product application. Applicants of drug approvals must comply with USP National Formulary (NF) standards, if applicable. The guidance assists these applicants in using the USP–PMP to request a revision of compendial standards.
In the past, if proposed specifications in a drug application appeared to not comply with the current USP monograph, FDA approval of the application would be delayed. Until the USP–PMP was established, there was not a process for drug developers to request changes to compendial standards for products that were not yet approved by FDA. This draft guidance describes the process for the “revision of compendial standards that are harmonized with the approved quality and labeling requirements for a drug product application,” including how to initiate the USP–PMP process.
Source: FDA
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
